Focal spasticity in multiple sclerosis: Treatment-goal attainment evaluation after botulinum toxin type A therapy and physical rehabilitation
Sign Up to like & getrecommendations! Published in 2018 at "Toxicon"
DOI: 10.1016/j.toxicon.2018.11.037
Abstract: Botulinum toxin type A (BT-A) is effective in reducing focal spasticity. A few data, instead, are available on its efficacy in improving motor function and quality of life, mostly in Multiple Sclerosis (MS) patients. It… read more here.
Keywords: toxin type; treatment; focal spasticity; multiple sclerosis ... See more keywords
Do randomised controlled trials evaluating functional outcomes following botulinum neurotoxin-A align with focal spasticity guidelines? A systematic review
Sign Up to like & getrecommendations! Published in 2022 at "Disability and Rehabilitation"
DOI: 10.1080/09638288.2021.2011437
Abstract: Abstract Purpose The impact of botulinum neurotoxin-A (BoNT-A) on functional outcomes when managing focal muscle spasticity remains unclear. It is possible that randomised controlled trial (RCT) design and/or reporting may be a contributing factor. The… read more here.
Keywords: functional outcomes; spasticity; randomised controlled; spasticity guidelines ... See more keywords